Pre-Filled Syringes: World Market Outlook 2011-2021

NEW YORK, Aug. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pre-Filled Syringes: World Market Outlook 2011-2021

http://www.reportlinker.com/p0578541/Pre-Filled-Syringes-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

How will the pre-filled syringes market develop this decade? Our new report shows you potential revenues to 2021 for that technology and its applications, discussing opportunities and prospects.

Our report covers pre-filled syringes in therapeutic applications: devices and drugs. Through our research and analysis we aim to save you time and help in your decisions.

You will find potential revenues for pre-filled syringe technologies at total world, submarket and national levels to 2021. What technologies and applications will expand that market? You will find predictions and answers in our report, including forecasted sales by unit.

We forecast revenues for pre-filled syringe devices, pen systems and autoinjectors. You will see how those products are changing the market and where technologies are heading.

You will also discover commercial prospects for pre-filled applications, including forecasted revenues for leading injectable drugs and their product classes: 

• Monoclonal antibodies

• Insulins

• Erythropoietin products

• Interferons

• Granular-colony stimulating factors (G-CSF)

• Recombinant coagulation factors

• Vaccines

• Biosimilars.

In particular, you will find discussions of Abbott Laboratories, Becton, Dickinson and Company, Vetter Pharma-Fertigung, SCHOTT, Ypsomed, Gerresheimer and MGlas. 

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions

You will find revenue forecasts, growth rates, market shares, a SWOT/STEP review, opinions from our survey and discussions of technologies and companies. We provide 120 tables and charts and three research interviews (shown in the accompanying lists).

Pre-Filled Syringes: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• You will discover revenue forecasts to 2021 for the world pre-filled syringes market and its main components, seeing where revenue growth will occur

• You will see a forecast of pre-filled syringe unit sales at world level

• You will find revenue predictions to 2021 for technologies, with discussions

• You will discover revenue forecasts to 2021 for injectable drug classes

• You will receive revenue forecasts to 2021 for leading injectable drugs - Lantus, Novorapid, Humalog, Humira, Enbrel, Neulasta, Avonex, Rebif and others

• You will find revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France,Spain, Italy, China and India - seeing growth trends

• You will assess leading companies for pre-filled syringes, analysing their activities, R&D and commercial outlooks

• You will examine established and emerging pre-filled drug technologies, seeing where the industry is heading

• You will investigate competition and opportunities influencing the industry and market from 2011 onwards

• You will see what will stimulate and restrain the industry and market from 2011

• You will analyse opportunities and challenges for established companies and those seeking to enter the pre-filled syringe market

• You will receive three interviews with authorities on pre-filled syringe technologies.

That mix of quantitative and qualitative analysis sets our report apart. We tackle crucial questions in the pre-filled syringes industry and market, aiming to benefit your work.

Order our report now to gain industry and market analysis for pre-filled syringe technologies

Our report is for everybody interested in market analysis, product development, sales and marketing for injected drug delivery systems and injectable drugs. You will find predictions and answers. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 Pre-Filled Syringes Market Review

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to Pre-Filled Syringes

2.1 The Pre-Filled Syringe Market

2.1.1 Market Overview

2.1.2 An Increasingly Alluring Sector

2.1.3 Greater Prevalence of Pre-Filled Syringes

2.1.4 Pre-Filled Syringes: The Current Situation

2.2 Introduction to Syringe Technology

2.2.1 A Brief Historical Perspective

2.3 The Design and Construction of Pre-Filled Syringes 

2.3.1 Pre-Filled Syringe Components

2.3.2 Silicone and Biotechnology Products

2.3.3 Material Choice: Glass or Plastic?

2.3.4 Syringe Operation: Manual vs. Mechanical

2.3.5 Pharmaceutical Development: Extractables, Leachables and Manufacturing Residuals

2.3.6 Pharmaceutical Development: Functional Testing of Delivery Systems

2.4 Pre-Filled Syringes Offer Convenience over Alternatives 

2.4.1 Pre-Filled Syringes for Lyophilized Drugs

2.5 Needle Stick Injuries and the Drive Towards Pre-Filled Syringes

2.5.1 Blood-Borne Pathogens and Needle Stick Injury

2.5.2 Accidental Needle Stick Injuries: a Serious Healthcare Problem

2.6 Injection Delivery Devices

2.6.1 Pen Injectors

2.6.2 Insulin Pens

2.6.3 Auto-Injectors

2.6.4 Needle-Free Injectors

2.6.5 Selection of Injection Devices

3. The World Pre-Filled Syringes Technology Market, 2011-2021

3.1 The World Pre-Filled Syringes Market in 2010 

3.2 Growing Market for Pre-Filled Syringes

3.2.1 Sales Forecast for Pre-Filled Syringe Units, 2010-2015

3.2.2 Sales Forecast for Pre-Filled Syringe Units, 2016-2021

3.2.3 Sales Forecast for Pen Systems and Autoinjectors Market, 2010-2015

3.2.4 Sales Forecast for Pen Systems and Autoinjectors Market, 2016-2021

3.2.5 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2010-2015

3.2.6 Sales Forecast for Other Pre-Filled Syringe Systems Market, 2016-2021

3.2.7 Sales Forecast for Total Pre-Filled Syringes Market, 2010-2015

3.2.8 Sales Forecast for Total Pre-Filled Syringes Market, 2016-2021

3.2.9 Summary: Overall World Pre-Filled Syringes Market, 2010-2021

3.3 Leading National Markets for Pre-Filled Syringes, 2010-2021

3.3.1 The US Pre-Filled Syringe Market, 2010-2021

3.3.2 The Japanese Pre-Filled Syringe Market, 2010-2021

3.3.3 The Leading European Pre-Filled Syringe Markets, 2010-2021

3.3.4 Emerging-Economy Pre-Filled Syringe Markets

3.3.5 The Chinese Pre-Filled Syringe Market, 2010-2021

3.3.6 The Indian Pre-Filled Syringe Market, 2010-2021

3.4 Summary of National Market Forecasts

4. Worldwide Market for Pre-Filled Syringes and Related Technology

4.1 Therapeutic Areas Offering Growth Opportunities

4.2 Development of Biologics and Vaccines Will Drive the Pre-Filled Syringes Market from 2011-2021

4.3 The Leading Sectors of Biological Drugs Market, 2010

4.3.1 Monoclonal Antibodies Currently Lead the Biologics Market

4.3.1.1 Long-Term Prospects for Monoclonal Antibodies and Implications for the Pre-Filled Syringes Market

4.3.2 The Human Insulins Class Will Exhibit Strong Growth 

4.3.3 Erythropoietin Products - How Will Reported Safety Affect Sales?

4.3.3.1 Erythropoietin Products Forecast, 2011-2021

4.3.4 The Interferons Class will Show an Increase in Revenues from 2011-2015

4.3.4.1 Long-Term Forecast for the Interferons Class

4.3.5 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2011-2021

4.3.6 Recombinant Coagulation Factors Will Show Steady Growth

4.3.7 Other Therapeutic Proteins

4.3.8 The Biosimilars Market, 2010

4.3.8.1 Forecast for the World Biosimilars Market, 2011-2021

4.3.9 Forecast for the Vaccines Market, 2011-2021

4.4 The Pre-Filled Syringe Drug Market: Conclusions

5. Leading Pre-Filled Syringe Products on the Market

5.1 Introduction

5.2 Insulins and Antidiabetic Agents

5.2.1 Leading Human Insulins and Analogues 

5.2.1.1 Lantus

5.2.1.2 Humalog

5.2.1.3 Novorapid

5.2.1.4 NovoMix/NovoLog

5.2.1.5 Levemir

5.2.1.6 Actraphane HM

5.3 Byetta/Exenatide LAR: Non-Insulin Revolutionary Injectable

5.3.1 Byetta's Strengths

5.3.2 Restraints on Byetta

5.4 Leading Biotech Products in Pre-Filled Syringe Format

5.4.1 Humira 

5.4.1.1 Humira - Leading Biotech Drug

5.4.1.2 Humira Market Forecast, 2011-2015 

5.4.1.3 Long-Term Prospects for Humira

5.4.2 Enbrel 

5.4.2.1 Amgen Continues to Benefit from Enbrel Sales

5.4.2.2 Enbrel Sales Will Show an Initial Increase 

5.4.2.3 Study Eases Fears of TNF Blocker Cancer Risk

5.4.2.4 New Enbrel Delivery System

5.4.2.5 Enbrel Lifecycle Management

5.4.2.6 Sales of Enbrel Will Eventually Decline

5.4.2.7 Enbrel Faces Competition from Several Other Biotech Drugs

5.4.2.8 Competition from Biosimilars?

5.4.3 Neulasta 

5.4.3.1 Neulasta Sales Forecast, 2011-2021

5.5 Other Pre-Filled Drugs on the Market

5.5.1 Avonex 

5.5.1.1 Avonex Market Forecast, 2011-2021

5.5.1.2 Avonex Faces Competition from New Oral MS Drugs

5.5.2 Rebif 

5.5.2.1 Rebiject II

5.5.2.2 RebiSmart 

5.5.2.3 Rebif Sales Forecast, 2011-2015

5.5.2.4 Rebif Sales Forecast, 2016-2021

6. Leading Companies in the Pre-Filled Syringe Field

6.1 Introduction

6.2 Becton, Dickinson and Company (BD)

6.2.1 Overview

6.2.2 Global Presence

6.2.3 Distribution

6.2.4 Focus on Parenteral and Biomaterial Technologies

6.2.5 Products

6.2.5.1 BD Hypak SCF Syringe Systems

6.2.5.2 BD Sterifill SCF Syringe Systems

6.2.5.3 Self-Injection Systems

6.2.5.3.1 BD Physioject Disposable AutoInjector

6.2.5.3.2 BD MicroInfusor Automatic Injection System

6.2.5.3.3 BD Liquid Dry Injector Disposable Pen Injector

6.2.5.3.4 BD Pens

6.2.5.4 Detachable and Integrated Safety Systems

6.2.5.5 BD Soluvia Pre-Fillable Microinjection System

6.2.5.6 BD Uniject SCF: Auto-Disable Injection System

6.2.6 R&D

6.2.7 Revenues

6.3 Vetter Pharma-Fertigung

6.3.1 Overview

6.3.2 Global Presence

6.3.3 Business Interests

6.3.3.1 Vetter Development Service 

6.3.3.2 Vetter Commercial Manufacturing 

6.3.3.3 Vetter Solutions

6.3.4 Capabilities

6.3.5 R&D

6.3.6 Product Focus

6.3.6.1Dual-Chamber Technology

6.3.6.2 Single-Chamber Syringes and Cartridges

6.3.7 Future Outlook

6.4 SCHOTT

6.4.1 Overview

6.4.2 Global Presence

6.4.3 SCHOTT's Pharmaceutical Systems

6.4.4 SCHOTT's Pharmaceutical Packaging Business Segment

6.4.5 Products: Pre-Fillable Polymer Syringes 

6.4.5.1 SCHOTT TopPac Pre-Fillable Syringes 

6.4.5.2 SCHOTT InJentle: Innovative Staked Needle Syringe 

6.4.6 Revenues 

6.5 Abbott Laboratories

6.5.1 Overview

6.5.2 Market Areas and Products

6.5.3 Pre-Filled Syringe Products: Humira

6.5.4 Abbott's Other Syringe Products

6.5.4.1 Abbott Abboject

6.5.4.2 Abbott LifeShield

6.5.4.3 Abbott Ansyr

6.5.4.4 Abbott Carpuject Injector 

6.5.5 Revenues and Growth

6.6 Ypsomed

6.6.1 Overview

6.6.2 Global Presence

6.6.3 Products

6.6.3.1 Insulin Pen Injectors 

6.6.3.2 Pen Injectors for Other Indications

6.6.3.3 Monodose Pens for Dual-Chamber Cartridges

6.6.3.4 Disposable Auto-Injectors 

6.6.3.5 Standard Pen Needles Penfine and Clickfine

6.6.3.6 Safety Pen Needle Clickfine AutoProtect

6.6.4 R&D

6.6.5 Revenues and Growth

6.6.6 Future Outlook

6.7 Gerresheimer 

6.7.1 Overview

6.7.2 Business Operations

6.7.3 Locations

6.7.4 Gerresheiemer's Tubular Glass Division 

6.7.5 Syringe Systems

6.7.5.1 Technology Centre for Syringe Systems

6.7.5.2 Technical Competence Centre for Plastic Products 

6.7.6 Revenues

6.7.7 R&D

6.7.8 Outlook

6.8 MGlas (MG)

6.8.1 Overview

6.8.2 Products

6.8.2.1 Pre-Fillable Syringes/Cartridges/Vials

6.8.2.2 MG Innovative Needles

7. Analysis of Forces Influencing the Pre-Filled Syringes Industry and Market

7.1 Introduction

7.2 Commercial Drivers of the Pre-Filled Syringes Market 

7.2.1 Cost Savings - a Powerful Motivator?

7.2.2 Glass Pre-Fillable Syringes 

7.2.3 Plastic Pre-Fillable Syringes

7.2.4 Convenience and Safety Issues

7.2.5 Cost Efficiencies 

7.2.6 Product Differentiation and Customization 

7.2.7 Reimbursement 

7.3 Commercial Restraints for the Pre-Filled Syringes Market

7.3.1 Pre-Filled Syringe Systems Have Limitations

7.3.2 Patients Prefer Pills

7.4 Emerging Trends and Opportunities in the Pre-Filled Syringes Market: Opportunity Analysis

7.5 Challenges Facing the Pre-Filled Syringes Market

7.5.1 Needle Stick Safety and Prevention Laws 

7.5.1.1 Compliance with Needle Stick Safety and Prevention Laws

7.5.1.2 Main Findings Leading to the Legislation

7.5.1.3 Increasing Exposure to Blood-Borne Pathogens

7.5.1.4 OSHA 1991 Regulation Standard

7.5.1.5 Estimated Needle Stick and Other Percutaneous Injuries Occurring Annually in the US

7.5.1.6 Newer Engineering Controls and Safer Medical Devices

7.5.1.7 CDC Estimates 80% of Sharps Injuries Are Preventable

7.5.1.8 OSHA 200 Log Surveillance System

7.5.1.9 Training and Education

7.5.1.10 Summary of Regulatory and Legislative Requirements

7.5.2 State-Level OSHA Plans and Federal Legislation

7.5.3 BPS Enforcement by OSHA 

7.5.4 Laws in Other International Markets

7.5.5 EU on the Threshold of New Laws to Tackle Needle Stick Injuries

7.5.6 High Entry Barriers, Few Suppliers

7.5.7 Product Stability a Major Concern 

7.5.7.1 Leachables and Safety

7.5.7.2 Compatibility between Drug Product and Pre-Filled Syringes

7.5.7.3 Eprex and Leaching

7.5.7.4 Protein Aggregation Related to Leached Tungsten 

7.5.7.5 Protein Aggregation Related to Silicone Oil

7.5.8 Product Stability and Quality Assurance Programme 

7.5.8.1 A Paediatric H1N1 Vaccine Withdrawn from the Market

7.5.8.2 Voluntary Withdrawal of Five Lots of Flu Vaccine

7.5.8.3 Shelf Life of Some H1N1 Vaccine Batches Apparently Changed

7.5.8.4 Contamination Problems with Leachables in Pre-Fillable Syringes

7.5.8.5 West and Daikyo Offer Syringe Systems to Minimise Leaching

7.5.8.6 SCHOTT AG Launched InJentle Syringe to Improve Drug Stability

7.6 Conclusions

8. Opinions from Our Survey

8.1 Interview 1: Dr Phil Lever, Commercial Director,Cambridge Consultants, Cambridge, UK

8.1.1 Current Market Worth for Pre-Filled Syringes

8.1.2 Key Unmet Needs

8.1.3 Research and Development

8.1.4 Problems with the Current Use of Pre-Filled Syringes

8.1.5 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery

8.1.6 Drawbacks of Pre-Filled Syringes

8.1.7 Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices 

8.1.8 Complexities for Making New Pre-Filled Syringes

8.1.9 Preferred Component Materials, Surface Treatments and Filling Processes

8.1.10 Technologies, Developments and R&D

8.1.11 Main Therapeutic Areas Offering Growth Opportunities

8.1.12 The Future of PFS over the Next 10-15 Years

8.1.13 Main Threats Facing the PFS Industry

8.1.14 Novel Technology/Developments

8.1.15 Potential Replacement

8.2 Interview 2: Authority from a Company in the Sector (Views Provided Anonymously)

8.2.1 Unmet Needs and Market for Pre-Filled Syringes

8.2.2 Competing Products and Alternatives to Pre-Filled Syringes

8.2.3 Disadvantages and Drawbacks with Pre-Filled Syringes and Related Devices

8.2.4 Pre-Filled Syringe Products, Safety and Vaccines 

8.2.5 Challenges for Complex Biological Therapeutics in Pre-Filled Syringes

8.2.6 Versatility of Pre-Filled Syringes

8.2.7 Dual-Chamber Pre-Filled Syringe Systems

8.2.8 Syringe Material: Glass vs. Plastic

8.2.9 Future Developments in Pre-Filled Syringe Systems

8.2.10 Progress in Needle Stick Injury (NSI) Legislation for Europe

8.2.11 NSI Legislation and Implications for Stakeholders

 8.3 Interview 3: Dr Marja van der Heijden, Pharmaceutical Formulations Scientist, Abbott Healthcare Products B.V., Weesp, Netherlands

8.3.1 The Main Unmet Needs

8.3.2 Research and Development

8.3.3 Research Challenges Facing Pre-Filled Syringe Technology

8.3.4 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery

8.3.5 Drawbacks of Pre-Filled Syringes

8.3.6 Technologies, Developments and R&D

9. Conclusions from Our Research and Analyses

9.1 Introduction

9.2 Leading Players in the Market

9.3 Commercial Drivers of the Pre-Filled Syringe Market

9.4 Future Outlook

9.4.1 Further Advances?

9.4.2 Future Developments in Pre-Filled Syringe Systems

9.5 Concluding Remarks

List of Tables

Table 2.1 Summary of Drivers for Growth in the Pre-Filled Syringes Market, 2011

Table 2.2 Historical Timeline for Development of Syringe Technology

Table 2.3 Components for Pre-Fillable Syringes

Table 2.4 Leading Brands of Insulin in Pen Syringe Format, 2010

Table 2.5 Main Factors Increasing the Interest in Auto-Injectors, 2011

Table 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010-2015

Table 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2016-2021

Table 3.3 Pen Systems and Autoinjectors: World Sales Forecast, 2010-2015

Table 3.4 Pen Systems and Autoinjectors: World Sales Forecast, 2016-2021

Table 3.5 Other Pre-Filled Syringes: World Sales Forecast, 2010-2015

Table 3.6 Other Pre-Filled Syringes: World Sales Forecast, 2016-2021

Table 3.7 Total Pre-Filled Syringes: World Sales Forecast, 2010-2015

Table 3.8 Total Pre-Filled Syringes: World Sales Forecast, 2016-2021

Table 3.9 Worldwide Pre-Filled Syringes Market: Sales Forecasts, 2010-2015

Table 3.10 Worldwide Pre-Filled Syringes Market: Sales Forecasts, 2016-2021

Table 3.11 Leading Pre-Filled Syringe National Market Forecasts, 2010-2021

Table 4.1 Leading Product Classes Driving the Pre-Filled Syringes Market, 2010

Table 4.2 List of Some Currently Marketed Monoclonal Antibodies, 2011

Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2010-2015

Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2016-2021

Table 4.5 Insulins Market: World Sales Forecast, 2010-2015

Table 4.6 Insulins Market: World Sales Forecast, 2016-2021

Table 4.7 Erythropoietins Market: World Sales Forecast, 2010-2015

Table 4.8 Erythropoietins Market: World Sales Forecast, 2016-2021

Table 4.9 List of Some Currently Marketed Interferon Drugs, 2011

Table 4.10 Interferons Market: World Sales Forecast, 2010-2015

Table 4.11 Interferons Market: World Sales Forecast, 2016-2021

Table 4.12 G-CSF Market: World Sales Forecast, 2010-2015

Table 4.13 G-CSF Market: World Sales Forecast, 2016-2021

Table 4.14 List of Some Currently Marketed Recombinant Coagulation Factors, 2011

Table 4.15 Recombinant Coagulations Factors Market: World Sales Forecast, 2010-2015

Table 4.16 Recombinant Coagulations Factors Market: World Sales Forecast, 2016-2021

Table 4.17 List of Some Marketed Human Growth Hormones, 2011

Table 4.18 List of Some Currently Marketed Pre-Filled Immunosuppressants Products, 2011

Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2010-2015

Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2016-2021

Table 4.21 List of Some Currently Marketed Biosimilar Drugs, 2011

Table 4.22 Biosimilars Market: World Sales Forecast, 2010-2015

Table 4.23 Biosimilars Market: World Sales Forecast, 2016-2021

Table 4.24 List of Some Currently Marketed Vaccines, 2011

Table 4.25 Total Vaccines Market: World Sales Forecast, 2010-2015

Table 4.26 Total Vaccines Market: World Sales Forecast, 2016-2021

Table 5.1 Anti-Diabetic Agents Available in Pre-Filled Syringe Format, 2011

Table 5.2 Lantus: World Sales Forecast, 2010-2015 

Table 5.3 Lantus: World Sales Forecast, 2016-2021 

Table 5.4 Humalog: World Sales Forecast, 2010-2015 

Table 5.5 Humalog: World Sales Forecast, 2016-2021 

Table 5.6 Novorapid: World Sales Forecast, 2010-2015 

Table 5.7 Novorapid: World Sales Forecast, 2016-2021 

Table 5.8 NovoMix/NovoLog: World Sales Forecast, 2010-2015 

Table 5.9 NovoMix/NovoLog: World Sales Forecast, 2016-2021 

Table 5.10 Levemir: World Sales Forecast, 2010-2015 

Table 5.11 Levemir: World Sales Forecast, 2016-2021 

Table 5.12 Actraphane HM: World Sales Forecast, 2010-2015 

Table 5.13 Actraphane HM: World Sales Forecast, 2016-2021 

Table 5.14 Byetta: World Sales Forecast, 2010-2015

Table 5.15 Byetta: World Sales Forecast, 2016-2021

Table 5.16 Humira: World Sales Forecast, 2010-2015

Table 5.17 Humira: World Sales Forecast, 2016-2021

Table 5.18 Enbrel: World Sales Forecast, 2010-2015 

Table 5.19 Enbrel: World Sales Forecast, 2016-2021 

Table 5.20 Neulasta: World Sales Forecast, 2010-2015 

Table 5.21 Neulasta: World Sales Forecast, 2016-2021 

Table 5.22 Avonex: World Sales Forecast, 2010-2015 

Table 5.23 Avonex: World Sales Forecast, 2016-2021 

Table 5.24 Rebif: World Sales Forecast, 2010-2015 

Table 5.25 Rebif: World Sales Forecast, 2016-2021 

Table 5.26 Some Leading Pre-Filled Syringe Vaccine Products on Market, 2011

Table 6.1 Leading Companies in Pre-Filled Syringes Market, 2011

Table 7.1 SWOT Analysis of World Pre-Filled Syringes Market: Strengths, 2010-2021

Table 7.2 SWOT Analysis of World Pre-Filled Syringes Market: Weaknesses, 2010-2021

Table 7.3 SWOT Analysis of World Pre-Filled Syringes Market: Opportunities and Threats, 2010-2021

Table 7.4 Risk of Infection Following Needle Stick Incident, 2011

Table 7.5 Examples of Leachables Impacting on Safety and Product Quality

Table 9.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010, 2012, 2015, 2017, 2019 and 2021

Table 9.2 Pre-Filled Syringes: World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 and 2021

List of Figures

Figure 3.1 Pre-Filled Syringes: World Unit Sales Forecast, 2010-2015

Figure 3.2 Pre-Filled Syringes: World Unit Sales Forecast, 2016-2021

Figure 3.3 Pen Systems and Autoinjectors: World Sales Forecast, 2010-2015

Figure 3.4 Pen Systems and Autoinjectors: World Sales Forecast, 2016-2021

Figure 3.5 Other Pre-Filled Syringes: World Sales Forecast, 2010-2015

Figure 3.6 Other Pre-Filled Syringes: World Sales Forecast, 2016-2021

Figure 3.7 Total Pre-Filled Syringes Market: World Sales Forecast, 2010-2015

Figure 3.8 Total Pre-Filled Syringes Market: World Sales Forecast, 2016-2021

Figure 3.9 US and Other Leading Pre-Filled Syringe Market Forecasts, 2010-2021

Figure 3.10 Leading National Pre-Filled Syringe Market Forecasts (Lower Range), 2010-2021

Figure 3.11 Pre-Filled Syringe Sales in Leading National Markets, 2010

Figure 3.12 Pre-Filled Syringe Sales in Leading National Markets, 2015

Figure 3.13 Pre-Filled Syringe Sales in Leading National Markets, 2018

Figure 3.14 Pre-Filled Syringe Sales in Leading National Markets, 2021

Figure 4.1 Monoclonal Antibodies Market: World Sales Forecast, 2010-2021

Figure 4.2 Insulins Market: World Sales Forecast, 2010-2021

Figure 4.3 Erythropoietins Market: World Sales Forecast, 2010-2021

Figure 4.4 Interferons Market: World Sales Forecast, 2010-2021

Figure 4.5 G-CSF Market: World Sales Forecast, 2010-2021

Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2010-2021

Figure 4.7 Other Therapeutic Proteins Market: World Sales Forecast, 2010-2021

Figure 4.8 Biosimilars Market: World Sales Forecast, 2010-2021

Figure 4.9 Vaccines Market: World Sales Forecast, 2010-2021

Figure 5.1 Lantus: World Sales Forecast, 2010-2021 

Figure 5.2 Humalog: World Sales Forecast, 2010-2021 

Figure 5.3 Novorapid: World Sales Forecast, 2010-2021 

Figure 5.4 NovoMix/NovoLog: World Sales Forecast, 2010-2021 

Figure 5.5 Levemir: World Sales Forecast, 2010-2021

Figure 5.6 Actraphane HM: World Sales Forecast, 2010-2021

Figure 5.7 Byetta: World Sales Forecast, 2010-2021 

Figure 5.8 Humira: World Sales Forecast, 2010-2021

Figure 5.9 Enbrel: World Sales Forecast, 2010-2021

Figure 5.10 Neulasta: World Sales Forecast, 2010-2021

Figure 5.11 Avonex: World Sales Forecast, 2010-2021

Figure 5.12 Rebif: World Sales Forecast, 2010-2021

Figure 6.1 BD Medical Sales Revenues: Fiscal Year, 2010

Figure 6.2 SCHOTT Sales Revenues by Region, 2009-2010

Figure 6.3 Abbott's Net Sales Worldwide, 2007-2010

Figure 6.4 Distribution of Gerresheimer Workforce, 2010-2011

Figure 6.5 Gerresheimer Sales by Division, 2010

Figure 6.6 Gerresheimer Sales by Region, 2010

Figure 7.1 Preference for Pre-Filled Syringes by Healthcare Professionals, 1995-1999

Figure 7.2 Pattern of Sharps Injury to Healthcare Workers, 1995-1999

Figure 9.1 Pre-Filled Syringes: World Revenue and Unit Sales Forecast, 2010-2021

Companies Listed

Abbott Laboratories 

Albert David

Alkermes

Alshifa Medical Syringes Manufacturing Company

Althea Technologies

Amgen

Amylin Pharmaceuticals

Astellas Pharma 

AstraZeneca

Avitro

B. Braun Medical

Battelle Medical Device Solutions

Baxter International 

Bayer

BD Biosciences

BD Healthcare Consulting & Services (BDHCS)

BD Pharmaceutical Systems

Becton, Dickinson and Company

Berna Biotech

Biogen Idec

Bioject Medical Technologies

Biopartners

Boston Scientific Corp.

C. R. Bard.

Cambridge Antibody Technology (now a part of AstraZeneca)

Cambridge Consultants

Catalent Pharma Solutions 

Centers for Disease Control and Prevention (CDC) [US]

Centocor Ortho Biotech

Chugai Pharmaceutical (a subsidiary of Roche Holding AG.)

Coeur

Covidien

CSL Behring

CSL Biotherapies

CT Arzneimettel

Daikyo Seiko

Disetronic Group

Disetronic Holding

Dong-A

Dongbao 

Eisai

Eli Lilly

E. R. Squibb & Sons 

European Medicines Agency (EMEA/EMA)

European Society for Medical Oncology

Flamel Technologies

Food and Drug Administration (FDA) [US]

Gate Pharmaceuticals

Genentech

GeneScience Pharmaceutical Co.

Genzyme

Gerresheimer

GlaxoSmithKline 

Henke-Sass Wolf

Hindustan Syringes and Medical Devices

Hi-Tech Medical Products

Hospira

Human Genome Sciences

Hyaluron Contract Manufacturing

Immunex

Insulet Corp

International Medication Systems 

Johnson & Johnson

LG Life Sciences

Life-Shield Products

Medex

Merck & Co.

Merck Serono

Merit Medical Systems

MG Sterile Products

MGlas

Milestone Scientific

Ministry for Health, Labor and Welfare [Japan] 

National Health Service (NHS) [UK] 

Novartis

Novo Nordisk

Nycomed

Occupational Safety and Health Administration (OSHA) [US]

Organon Teknika 

Otsuka Pharmaceutical

Owen Mumford

Pfizer

Pharmaceutical Research and Manufacturers ofAmerica (PhRMA) 

Plas-Pak Industries

PRC State Food and Drug Administration [China] 

Protalix Biotherapeutics 

Ratiopharm

Retractable Technologies

Revolutions Medical Corporation

Roche

Royal College of Nursing (RCN) [UK]

Safety Syringes

Sandoz

Sanofi Pasteur 

Sanofi (previously sanofi-aventis)

Schering-Plough

SCHOTT

Shanghai Celgen Bio-Pharmaceutical Co. 

Simponi

Smiths Medical International

Specialised Health Products International

Star Syringe

State Food and Drug Administration [China]

Takeda Pharmaceutical Company

Talecris Biotherapeutics

Terumo Medical Corporation

Teva Pharmaceutical Industries

The Research Foundation for Microbial Diseases ofOsaka University (BIKEN)

Tonghua Dongbao Pharmaceutical Co.

UCB

UltiMed

Unilife Medical Solutions

Vetter Pharma International

Vetter Pharma-Fertigung

Vita Needle Company

West Pharmaceutical Services

World Health Organization (WHO)

Wuxi Yushou Medical Appliances Co.

Wyeth (now part of Pfizer)

Ypsomed

To order this report:

In Vitro Diagnostic Industry: Pre-Filled Syringes: World Market Outlook 2011-2021

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker